Your Trusted Partner for Respiratory Vaccines

Protect Against Respiratory Threats With Moderna

mNEXSPIKE®
COVID-19 Vaccine, mRNA

A different COVID-19 vaccine[1–4]

- ≥65 years of age
- 12–64 years of age with ≥1 underlying condition that puts them at high risk for severe outcomes from COVID-19

spikevax®
COVID-19 Vaccine, mRNA

The first and only FDA-approved COVID-19 vaccine for high-risk individuals as young as **6 months of age**[4–6]*

- ≥65 years of age
- 6 months–64 years of age with ≥1 underlying condition that puts them at high risk for severe outcomes from COVID-19

mRESVIA®
(Respiratory Syncytial Virus Vaccine)

The only **ready-to-use** RSV vaccine in a pre-filled syringe[7]

mRESVIA is ready to use once thawed

- ≥60 years of age
- 18–59 years of age who are at increased risk for LRTD caused by RSV

mNEXSPIKE® and SPIKEVAX® INDICATION

mNEXSPIKE® (COVID-19 Vaccine, mRNA) and SPIKEVAX® (COVID-19 Vaccine, mRNA) are vaccines indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

mNEXSPIKE is approved for use in individuals who are:

- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

SPIKEVAX is approved for use in individuals who are:

- 65 years of age and older, or
- 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

mNEXSPIKE and SPIKEVAX IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer mNEXSPIKE® or SPIKEVAX® to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of mNEXSPIKE or SPIKEVAX or to individuals who had a severe allergic reaction following a previous dose of SPIKEVAX or any Moderna COVID-19 vaccine authorized for emergency use.

mRESVIA® INDICATION

mRESVIA® (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.

mRESVIA IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer mRESVIA® to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.

*Children and adolescents with ≥1 underlying condition are at increased risk for severe COVID-19 outcomes. Select underlying conditions include medical complexity, genetic, neurologic, and metabolic conditions, congenital heart disease, obesity, diabetes, asthma or chronic lung disease, sickle cell disease, and immunocompromised status.[6] Risk for severe COVID-19 outcomes in adults increases with age and presence of ≥1 underlying conditions. Select underlying conditions include cancer, cerebrovascular disease, chronic kidney disease, chronic liver diseases, chronic lung diseases, diabetes type 1 and 2, heart conditions, and overweight or obesity.[6]

Please see continued IMPORTANT SAFETY INFORMATION throughout, and scan the QR codes on the back for mNEXSPIKE Full Prescribing Information, SPIKEVAX Full Prescribing Information, and mRESVIA Full Prescribing Information.

moderna®

Experts recommend COVID-19 vaccination to help protect patients against severe outcomes

The CDC recommends vaccination for the prevention of COVID-19 disease and its complications for the 2025–2026 season[5]

Adults aged ≥65 years

Vaccination based on individual-based decision-making*

≥2 doses of the 2025–2026 vaccine recommended†

Individuals aged 6 months–64 years

Vaccination based on individual-based decision-making*—with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors

≥1 doses of the 2025–2026 vaccine recommended

2nd dose of 2025–2026 COVID-19 vaccine recommended at 6 months after 1st dose for eligible patients (minimum interval of 2–3 months, based on the product)[5†]

FOR THE 2023–2024 SEASON

2nd dose uptake in adults 65+ was ONLY 8.9%[8‡]



REMEMBER FOR THE 2025–2026 SEASON[5]

You can still help protect those who need a 2nd dose†

Review the full CDC 2025–2026 COVID-19 Vaccination Guidance for complete details on 2nd dose eligibility and dosing schedule

mNEXSPIKE AND SPIKEVAX IMPORTANT SAFETY INFORMATION (CONT.)

Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mNEXSPIKE or SPIKEVAX.

mRESVIA IMPORTANT SAFETY INFORMATION (CONT.)

Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.

Please see continued IMPORTANT SAFETY INFORMATION throughout, and scan the QR codes on the back for mNEXSPIKE Full Prescribing Information, SPIKEVAX Full Prescribing Information, and mRESVIA Full Prescribing Information.

Moderna is ready for you

REMEMBER

The 2025–2026 season is not over—vaccinate against COVID-19 today

RECOMMEND

A second dose of 2025–2026 COVID-19 vaccine for appropriate individuals[5†]

BE READY

The procurement window for COVID-19 vaccine supply for the 2026–2027 season ***opens in April***[§]

You may ***order*** RSV vaccine supply for eligible patients today

Procure vaccines via:

modernadirect.com



Scan the QR code to **create your Moderna Direct account** or **login** to your existing account.

— *OR* —

One of our authorized distributor partners



Scan the QR code to learn more about our **authorized distributors**.

*Also known as shared clinical decision-making. †Adults aged ≥65 years are recommended to receive 2 doses of 2025–2026 vaccine 6 months apart (minimum interval 2 months for Spikevax [COVID-19 Vaccine, mRNA], NUVAXOVID™ [COVID-19 Vaccine, Adjuvanted], or COMIRNATY® [COVID-19 Vaccine, mRNA]; minimum interval 3 months for mNEXSPIKE [COVID-19 Vaccine, mRNA]) based on individual-based decision-making. Moderately or severely immunocompromised individuals aged ≥6 months who are unvaccinated should receive a multidose initial series with an age-appropriate 2025–2026 COVID-19 vaccine and 1 dose of a 2025–2026 COVID-19 vaccine 6 months (minimum interval 2 months for Spikevax, NUVAXOVID, or COMIRNATY; minimum interval 3 months for mNEXSPIKE) after completing the initial series based on individual-based decision-making. Moderately or severely immunocompromised individuals aged ≥6 months who have previously completed the multidose initial series should receive 2 age-appropriate doses of 2025–2026 COVID-19 vaccine 6 months (minimum interval 2 months for Spikevax, NUVAXOVID, or COMIRNATY; minimum interval 3 months for mNEXSPIKE) apart based on individual-based decision-making. ‡Data from March 30, 2024, through June 29, 2024. §Reservations of COVID-19 vaccines subject to FDA approval of 2026–2027 formulas.

mNEXSPIKE AND SPIKEVAX IMPORTANT SAFETY INFORMATION (CONT.)

Warnings and Precautions (cont.)

- **Myocarditis and Pericarditis:** Postmarketing data with authorized or approved mRNA COVID-19 vaccines have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.
- **Syncope (fainting):** May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

mRESVIA IMPORTANT SAFETY INFORMATION (CONT.)

Warnings and Precautions (cont.)

- **Syncope:** Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
- **Altered Immunocompetence:** Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

Please see continued IMPORTANT SAFETY INFORMATION throughout, and scan the QR codes on the back for mNEXSPIKE Full Prescribing Information, SPIKEVAX Full Prescribing Information, and mRESVIA Full Prescribing Information.

mNEXSPIKE AND SPIKEVAX IMPORTANT SAFETY INFORMATION (CONT.)

Warnings and Precautions (cont.)

- **Altered Immunocompetence:** Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to mNEXSPIKE or SPIKEVAX.
- **Limitations of Vaccine Effectiveness:** mNEXSPIKE and SPIKEVAX may not protect all vaccine recipients.

Adverse Reactions

mNEXSPIKE

The most commonly reported (≥10%) adverse reactions were pain at the injection site, fatigue, headache, myalgia, chills, arthralgia, axillary swelling or tenderness, and nausea/vomiting.

SPIKEVAX

The most commonly reported (>10%) adverse reactions in participants 6 - 36 months of age: irritability/crying, pain at the injection site, sleepiness, loss of appetite, fever, erythema, swelling at the injection site, and axillary (or groin) swelling/tenderness.

The most commonly reported (>10%) adverse reactions in participants 37 months and older were: pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary (or groin) swelling/tenderness, swelling at the injection site, fever, and erythema.

Reporting Adverse Events and Vaccine Administration Errors

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or https://vaers.hhs.gov.

Please scan the QR code or ask your representative for mNEXSPIKE Full Prescribing Information.

Please scan the QR code or ask your representative for SPIKEVAX Full Prescribing Information.

mRESVIA IMPORTANT SAFETY INFORMATION (CONT.)

Adverse Reactions

In a clinical trial conducted in participants 60 years of age and older, the most commonly reported (≥10%) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%) and chills (11.6%).

In a clinical trial conducted in participants 18 through 59 years of age at increased risk for LRTD caused by RSV, the most commonly reported (≥10%) adverse reactions were injection site pain (73.9%), fatigue (36.9%), headache (33.3%), myalgia (28.9%), arthralgia (22.7%), chills (19.9%), axillary (underarm) swelling or tenderness (17.1%), and nausea/vomiting (10.8%).

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please scan the QR code or ask your representative for mRESVIA Full Prescribing Information.

For Colorado and Connecticut price disclosure, please visit https://modernadirect.com/wac-disclosure.

CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus disease 2019; FDA, US Food and Drug Administration; LRTD, lower respiratory tract disease; mRNA, messenger RNA; RSV, respiratory syncytial virus.

References: 1. mNEXSPIKE Prescribing Information. Moderna; 2025. **2.** Chalkias S, et al. *J Infect Dis*. 2025;231(4):e754-e763. **3.** Montgomerie I, et al. *iScience*. 2023;26(4):106256. **4.** Spikevax Prescribing Information. Moderna; 2025. **5.** CDC. Accessed November 18, 2025. https://www.cdc.gov/covid/hcp/vaccine-considerations/index.html **6.** CDC. Accessed August 20, 2025. https://www.cdc.gov/covid/risk-factors/index.html **7.** mRESVIA Prescribing Information. Moderna; 2025. **8.** CDC. Accessed January 23, 2026. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/06-COVID-Roper-508.pdf

moderna